Table 8 Application of IHC in primary diagnosis in confirmed cases (some patterns, partially overlapping cases)
From: Re-evaluation of histological diagnoses of malignant mesothelioma by immunohistochemistry
Year | Confirmed cases | IHC/markers in primary diagnostics |
|---|---|---|
1980-2002 | 49 (100%) | |
19 (39%) | No IHC performed | |
4 (8%) | No information available about eventual IHC use | |
26 (53%) | IHC, 1 till 18 markers | |
No specific positive MM markers | ||
1988-1999 | 7 (14%) | CEA, Vimentin and Pan-Cytokeratin |
Broad spectrum of non-specific markers | ||
1996, 1997 | 2 (4%) | 15/18 markers, 1st one incl. positive marker HBME-1, otherwise no specific positive MM markers |
Positive MM markers | ||
1998-2002 | 8 (16%) | Calretinin, in all but one (1998) of cases combined with other markers, two cases with another positive marker - Thrombomodulin and HBME-1, respectively (n = 1-7) |
Negative MM markers | ||
1988-2002 | 17 (35%) | CEA, in all but one (1990) of cases combined with other markers (n = 1-18) |
1996, 2002 | 2 (4%) | CD15, combined with, amongst other markers, CEA and Ber-Ep4 (n = 15, 7) |
1996-2002 | 10 (20%) | Ber-Ep4, combined with other markers (n = 4-15) |